Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

804.34 +21.16 (+2.70%)
Streaming Delayed Price Updated: 12:42 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
78 79 Next >
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Investors are still excited about obesity treatments and weight-management drugs. 
Via The Motley Fool
S&P 500 Hits 5,000 Milestone, Yet Concerns Of Overvaluation Versus Its Equal-Weight Counterpart Mount
S&P 500 index at 5,000 points; caution signals emerge in comparison to equal-weight index. Magnificent Seven heavyweights contribute 64% of returns. 
Via Benzinga
Topics Stocks
Exposures US Equities
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development. 
Via Benzinga
4 Reasons Why 2024 Could Be Eli Lilly's Worst Year for the Rest of This Decade
Lilly's headwinds in 2024 should only be temporary challenges. 
Via The Motley Fool
LLY Vs NVO: Which One Is Likely To Become A $1T Company First
Tackling growing waistlines is expected to yield much shareholder value. 
Via Talk Markets
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
Via Investor's Business Daily
What's Going On Eli Lilly Stock Thursday?
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. 
Via Benzinga
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry
Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company. 
Via Benzinga
SPDR ETF Report For Wednesday, February 7
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day just ended, Wednesday, February 7 
Via Talk Markets
Topics ETFs
Apple, Chipotle And Eli Lilly Stocks Baffle Jim Cramer With Unusual Moves: 'Authentic Stupidity Is A Perfectly Plausible Explanation'
Cramer questioned the rationale behind the market's behavior, emphasizing that not all stock movements are logical, especially during earnings season. 
Via Benzinga
Triple Threat Of Key Reversals: Warning Shots Fired In 3 High Fliers
In a potential warning sign to investors, three high-flying stocks had key reversals on Tuesday. This means the stocks opened to new highs before trading below their previous closing price.  
Via Benzinga
Analysts Boost Eli Lilly's Forecast With High Hopes On Mounjaro, Zepbound Performance
Eli Lilly's SYNERGY-NASH Phase 2 study results and positive market outlook drive BMO's raised price target to $865. Morgan Stanley remains bullish on Mounjaro/Zepbound launch. BofA Securities cites... 
Via Benzinga
Abbott Laboratories Stock Getting Closer To Key Technical Benchmark
Abbott Laboratories shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
SPDR ETF Report For Tuesday, February 6
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day just ended, Tuesday, February 6 
Via Talk Markets
Topics ETFs
Eli Lilly (LLY) Q4 2023 Earnings Call Transcript
LLY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks
Thanks to weight loss and obesity drugs, Eli Lilly and Novo Nordisk could become the first trillion-dollar stocks in the pharma industry. 
Via InvestorPlace
Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?
At noon trading in New York, major equity indices on Wall Street remain directionless as traders evaluate the future course of monetary policy ahead of several speeches by Federal Reserve officials in... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Eli Lilly Stock Jumped as Much as 5.1% Today Then Gave Up Its Gains
Investors shouldn't worry that Lilly's gains quickly evaporated. 
Via The Motley Fool
Stocks In China Flying, Lifting Sentiment In Stock Markets Across The Globe, AI And Weight Loss Drugs Get Hotter
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Chips Vs. Oil: Nvidia Now Outweighs The S&P 500's Entire Energy Sector
Nvidia now has a market cap more than the combined value of the S&P 500 energy sector. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Dow Jumps Over 100 Points; Eli Lilly Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.34% to 38,509.84 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects 20% Revenue Increase In 2024
This surge is attributed to the popularity of Lilly's new diabetes drug, Mounjaro, and its anti-obesity medication, Zepbound. 
Via Benzinga
Investors Cheer Eli Lilly Earnings, Q4 Performance Surpasses Expectations Thanks To Strong Zepbound Launch, Surging Weight Loss Drug Sales
Eli Lilly beats Q4 2023 revenue expectations at $9.35 billion, driven by higher realized prices and strong sales of Mounjaro, Verzenio, and Jardiance. 
Via Benzinga
US Stocks Brace For Another Day In The Red As Rally Loses Steam: Analyst Sees Market Pullback On This Indicator
The stock rally that propelled the S&P 500 and the Dow to record highs last week seems to have stalled, with Fed officials remaining non-committal about rate-cut plans. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly Stock Veers Higher On Fourth-Quarter Beat
Eli Lilly Scored a strong Q4 win and provided healthy guidance Tuesday. Shares moved toward a profit-taking zone following a January breakout. 
Via Investor's Business Daily
Investor Sentiment Improves Following Services PMI; S&P 500 Slips From Record Levels
The CNN Money Fear and Greed index showed further improvement in overall market sentiment, but it remained in the "Greed" zone on Monday. U.S. stocks closed lower on Monday, with the S&P 500 index... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
78 79 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.